Last reviewed 2026-04-23 · How we verify

NXY-059

NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage.

NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage. Used for Acute ischemic stroke (within 6 hours of symptom onset).

At a glance

Mechanism of action

NXY-059 works by neutralizing reactive oxygen species and free radicals that are generated during cerebral ischemia and reperfusion, thereby reducing oxidative stress-induced neuronal injury. This neuroprotective approach aims to limit the expansion of the infarct core and improve neurological outcomes when administered acutely after stroke onset.

Approved indications

• Acute ischemic stroke (within 6 hours of symptom onset)

Common side effects

• Headache
• Nausea
• Fever
• Hypertension

Key clinical trials

• Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (PHASE2)
• Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC (PHASE1)
• Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE2)
• Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)
• Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NXY-059 CI brief — competitive landscape report
• NXY-059 updates RSS · CI watch RSS
• AstraZeneca portfolio CI